PFG Investments LLC Acquires 4,517 Shares of AbbVie Inc. $ABBV

PFG Investments LLC grew its holdings in AbbVie Inc. (NYSE:ABBV) by 14.2% during the 4th quarter, Holdings Channel reports. The firm owned 36,224 shares of the company’s stock after purchasing an additional 4,517 shares during the period. PFG Investments LLC’s holdings in AbbVie were worth $8,277,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of ABBV. Brighton Jones LLC boosted its stake in AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after acquiring an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC boosted its stake in AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after acquiring an additional 3,064 shares during the last quarter. Schnieders Capital Management LLC. boosted its stake in AbbVie by 5.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock worth $3,056,000 after acquiring an additional 789 shares during the last quarter. Ieq Capital LLC boosted its stake in AbbVie by 4.6% during the 2nd quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock worth $22,281,000 after acquiring an additional 5,274 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC boosted its stake in AbbVie by 117.3% during the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock worth $210,685,000 after acquiring an additional 612,702 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on ABBV shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. Cantor Fitzgerald lowered their price objective on shares of AbbVie from $250.00 to $240.00 and set an “overweight” rating on the stock in a report on Wednesday, April 8th. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Citigroup lowered their target price on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a report on Tuesday, January 27th. Finally, Evercore decreased their price objective on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a report on Wednesday, February 4th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $253.00.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Late‑breaking Phase 2 data for mirvetuximab (Elahere) in platinum‑sensitive ovarian cancer and an exclusive pain‑therapy licensing deal reinforce AbbVie’s longer‑term oncology and pain pipelines, supporting growth expectations. AbbVie Ovarian Cancer Data And Pain Deal Extend Long Term Story
• Positive Sentiment: AbbVie paid a reported upfront to secure global rights to RC148, signaling management is investing in external oncology/R&D assets to bolster future revenue streams and diversify the pipeline. RemeGen Receives US$650 Million Upfront from AbbVie for RC148 Global Rights
• Positive Sentiment: AbbVie reached a large licensing agreement with Haisco (reported near $715–$745M), which monetizes or out‑licenses assets while extending geographic reach for certain pain therapies—positive for pipeline monetization and incremental revenue potential. Pharmaceutical Executive Daily: AbbVie and Haisco Enter $745 Million Licensing Agreement
• Positive Sentiment: Early‑stage ABBV‑438 myeloma data continue to underscore AbbVie’s long‑term oncology ambitions; successful advancement would broaden oncology exposure beyond established franchises. AbbVie’s ABBV-438 Myeloma Trial: Early-Stage Bet on Long-Term Oncology Growth
• Neutral Sentiment: AbbVie remains a dividend candidate for income investors and appears in recent roundups of high‑yield healthcare names, which supports income‑oriented demand even if growth questions persist. Wall Street’s Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
• Neutral Sentiment: Commentary on AbbVie’s progress in the weight‑loss market highlights pipeline diversification but notes the company remains behind market leaders—an incremental positive but not an immediate revenue driver. Could AbbVie Crash Lilly’s Weight‑Loss Party?
• Negative Sentiment: Evercore ISI slightly lowered its price target on ABBV (to $232 from $233) while keeping an Outperform rating—an incremental analyst headwind that can pressure intraday sentiment despite the small magnitude. Evercore ISI Tweaks AbbVie (ABBV) Estimates, Lowers Price Target Marginally

AbbVie Stock Down 0.8%

ABBV opened at $208.58 on Thursday. The stock has a market capitalization of $368.80 billion, a price-to-earnings ratio of 88.38, a P/E/G ratio of 0.75 and a beta of 0.38. AbbVie Inc. has a twelve month low of $168.54 and a twelve month high of $244.81. The company has a 50-day simple moving average of $219.49 and a 200 day simple moving average of $223.78.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business’s quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Sell-side analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.3%. AbbVie’s payout ratio is presently 293.22%.

Insider Activity at AbbVie

In other news, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.06% of the company’s stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.